share_log

Akso Health Group (NASDAQ:AHG) Soars 95% This Week, Taking One-year Gains to 268%

Akso Health Group (NASDAQ:AHG) Soars 95% This Week, Taking One-year Gains to 268%

Akso Health Group(納斯達克股票代碼:AHG)本週飆升95%,使一年的漲幅達到268%
Simply Wall St ·  05/24 21:45

Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! For example, the Akso Health Group (NASDAQ:AHG) share price has soared 268% in the last 1 year. Most would be very happy with that, especially in just one year! And in the last week the share price has popped 95%. In contrast, the longer term returns are negative, since the share price is 14% lower than it was three years ago.

除非你借錢投資,否則潛在的損失是有限的。另一方面,如果你找到一家高質量的企業來收購(價格合適),你的錢可以翻一番以上!例如,阿克索健康集團(納斯達克股票代碼:AHG)的股價在過去1年中飆升了268%。大多數人會對此感到非常滿意,尤其是在短短一年內!而在上週,股價上漲了95%。相比之下,長期回報率爲負,因爲股價比三年前低了14%。

Since the stock has added US$89m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

由於該股僅在過去一週的市值就增加了8900萬美元,因此讓我們看看基礎表現是否推動了長期回報。

Akso Health Group wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

Akso Health Group在過去十二個月中沒有盈利,我們不太可能看到其股價與每股收益(EPS)之間存在很強的相關性。可以說,收入是我們的下一個最佳選擇。無利可圖的公司的股東通常希望強勁的收入增長。一些公司願意推遲盈利以更快地增加收入,但在這種情況下,人們希望良好的收入增長來彌補收益不足。

Akso Health Group actually shrunk its revenue over the last year, with a reduction of 87%. So we would not have expected the share price to rise 268%. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. Of course, it could be that the market expected this revenue drop.

實際上,Akso Health Group的收入比去年減少了87%。因此,我們沒想到股價會上漲268%。這是一個很好的例子,說明買家甚至在基本面指標顯示出大幅增長之前就可以推高價格。當然,可能是市場預期的收入下降。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下圖描述了收入和收入隨時間推移而發生的變化(點擊圖片即可顯示確切的數值)。

earnings-and-revenue-growth
NasdaqCM:AHG Earnings and Revenue Growth May 24th 2024
納斯達克股票代碼:AHG 收益和收入增長 2024 年 5 月 24 日

Take a more thorough look at Akso Health Group's financial health with this free report on its balance sheet.

通過這份免費的資產負債表報告,更全面地了解Akso Health Group的財務狀況。

A Different Perspective

不同的視角

It's good to see that Akso Health Group has rewarded shareholders with a total shareholder return of 268% in the last twelve months. Notably the five-year annualised TSR loss of 13% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Akso Health Group (at least 3 which are potentially serious) , and understanding them should be part of your investment process.

很高興看到Akso Health Group在過去十二個月中向股東提供了268%的總股東回報率。值得注意的是,五年期股東總回報率每年虧損13%,與最近的股價表現相比非常不利。長期虧損使我們保持謹慎,但短期股東總回報率的增長無疑暗示着更光明的未來。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,投資風險的幽靈無處不在。我們已經向Akso Health Group確定了4個警告信號(至少3個可能很嚴重),了解這些信號應該是您投資過程的一部分。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找獲利投資的人來說,這份最近進行內幕收購的被低估公司的免費清單可能只是入場券。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論